Table 2. Patient characteristics for... | Rockefeller University Press

Table 2.

Patient characteristics for IPAH in the immunohistochemical study

Pt	Age	Gender	PAP (s/d/m)	PVR	6MW	Medication
	yr		mmHg	dyn × s × cm⁻⁵ × m²
1	58	Female	66/37/50	685	298	Bosentan, Epoprostenol, Sildenafil, Treprostinil
2	7	Male	143/82/105	2,226	256	Bosentan, Epoprostenol, Sildenafil
3	43	Male	55/35/40	756	272	Bosentan, Sildenafil, Iloprost
4	47	Female	82/36/51	1,103	121	Bosentan, Epoprostenol, Sildenafil, Treprostinil
5	10	Female	103/43/62	1,400	460	Bosentan, Sildenafil, Iloprost, Treprostinil, Imatinib
6	15	Female	175/66/102	2,018	387	Epoprostenol, Sildenafil
7	16	Female	125/72/95	3,238	512	Bosentan, Epoprostenol, Sildenafil, Treprostinil
8	24	Male	113/70/88	1,356	182	Bosentan, Epoprostenol, Sildenafil
9	62	Female	67/22/37	1,018	278	Bosentan, Epoprostenol, Sildenafil
10	38	Female	89/26/50	1,170	288	Bosentan, Sildenafil

Pt	Age	Gender	PAP (s/d/m)	PVR	6MW	Medication
	yr		mmHg	dyn × s × cm⁻⁵ × m²
1	58	Female	66/37/50	685	298	Bosentan, Epoprostenol, Sildenafil, Treprostinil
2	7	Male	143/82/105	2,226	256	Bosentan, Epoprostenol, Sildenafil
3	43	Male	55/35/40	756	272	Bosentan, Sildenafil, Iloprost
4	47	Female	82/36/51	1,103	121	Bosentan, Epoprostenol, Sildenafil, Treprostinil
5	10	Female	103/43/62	1,400	460	Bosentan, Sildenafil, Iloprost, Treprostinil, Imatinib
6	15	Female	175/66/102	2,018	387	Epoprostenol, Sildenafil
7	16	Female	125/72/95	3,238	512	Bosentan, Epoprostenol, Sildenafil, Treprostinil
8	24	Male	113/70/88	1,356	182	Bosentan, Epoprostenol, Sildenafil
9	62	Female	67/22/37	1,018	278	Bosentan, Epoprostenol, Sildenafil
10	38	Female	89/26/50	1,170	288	Bosentan, Sildenafil

PAP, PA pressure (s, systolic; d, diastolic; m, mean); PVR, pulmonary vascular resistance; 6MW, distance (m) walked in 6 min.